内毒素水平: Less than 0.1 EU/μg of Recombinant HumanIGF-BP5 as determined by LAL method.
活性: Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit IGF-II induced proliferation of MCF-7 cells is less than 0.4 μg/ml, corresponding to a specific activity of > 2500 IU/mg in the presence of 15 ng/ml of Recombinant HumanIGF-II.
形态: Lyophilized from a 0.2 μm filtered concentrated solution in 10 mM Sodium Citrate, pH 3.0.
溶解方法: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
储存/保存方法: This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.